2000
Immunological Evidence that Non-carboxymethyllysine Advanced Glycation End-products Are Produced from Short Chain Sugars and Dicarbonyl Compounds in vivo
Takeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, Kameda Y. Immunological Evidence that Non-carboxymethyllysine Advanced Glycation End-products Are Produced from Short Chain Sugars and Dicarbonyl Compounds in vivo. Molecular Medicine 2000, 6: 114-125. PMID: 10859028, PMCID: PMC1949938, DOI: 10.1007/bf03401779.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodiesCattleChromatography, AffinityCross ReactionsDiabetes Mellitus, Type 2Enzyme-Linked Immunosorbent AssayGlycation End Products, AdvancedGlyceraldehydeGlyoxalHumansImmunoblottingKidney Failure, ChronicLysineMaillard ReactionOxidation-ReductionPyruvaldehydeRabbitsRenal DialysisConceptsAGE antibodyCML-AGEDiabetic patientsAGE-bovine serum albuminShort Chain SugarsAdvanced glycation end productsAnti-AGE antibodyGlycation end productsAutoxidation of sugarsImmunization of rabbitsCML-BSADiabetic serumSerum albuminAdvanced glycationAGE contentSugar autoxidationRabbit serum albuminAGE modificationAntibodiesImmunological evidenceApparent molecular weightPatientsAge 3AgeImmunoblot analysis
1997
Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia
Fishbane S, Bucala R, Pereira B, Founds H, Vlassara H. Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia. Kidney International 1997, 52: 1645-1650. PMID: 9407512, DOI: 10.1038/ki.1997.497.Peer-Reviewed Original ResearchMeSH KeywordsApolipoproteins BFemaleGlycation End Products, AdvancedHumansKidney Failure, ChronicMaleMiddle AgedProspective StudiesRenal DialysisUremiaConceptsAdvanced glycation endoproductsLow density lipoprotein clearanceLong-term hemodialysis therapyRenal replacement treatmentEffect of hemodialysisAGE removalDiabetic ESRDSerum apoBESRD patientsRenal insufficiencyClinical outcomesLipoprotein clearancePlasma apoBHemodialysis therapyReplacement treatmentApoliprotein BPatientsGroup subjectsHemodialysis filtersReactive substancesApoBPlasma apolipoproteinsAGE clearanceBaselineClearance
1996
The role of advanced glycosylation end-products in the pathogenesis of atherosclerosis
Makita Z, Yanagisawa K, Kuwajima S, Bucala R, Vlassara H, Koike T. The role of advanced glycosylation end-products in the pathogenesis of atherosclerosis. Nephrology Dialysis Transplantation 1996, 11: 31-33. PMID: 9044304, DOI: 10.1093/ndt/11.supp5.31.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseLow-density lipoproteinDiabetic patientsDevelopment of atherosclerosisAGE-LDLAdvanced glycosylationAGE-modified formCoronary artery diseaseSerum total cholesterolPathogenesis of atherosclerosisArtery diseaseDiabetes mellitusRenal diseaseTotal cholesterolCerebrovascular diseaseMarked elevationRapid progressionTissue injuryVascular pathologyNormal controlsPatientsAGE-modified peptidesAtherogenic formAtherosclerosisAGE modification